Related Experiment Video
Updated: May 22, 2026
08:02
Combination Radiotherapy in an Orthotopic Mouse Brain Tumor Model
Published on: March 6, 2012
Combining angiogenesis inhibition and radiotherapy: a double-edged sword
Esther A Kleibeuker1, Arjan W Griffioen, Henk M Verheul
1Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands.
Summary
Combining radiotherapy with angiogenesis inhibitors shows promise for cancer treatment. Optimal scheduling and dosing are crucial for maximizing efficacy and minimizing toxicity, as highlighted by recent clinical studies.
Area of Science:
- Oncology
- Radiotherapy
- Vascular Biology
Background:
- Radiotherapy often results in local treatment failure in cancer patients.
- Tumor growth necessitates angiogenesis (new blood vessel formation) for nutrient and oxygen supply.
- Angiostatic agents, which inhibit tumor angiogenesis, are approved cancer therapies.
Purpose of the Study:
- To review the opportunities and challenges of combining radiotherapy with angiostatic agents.
- To summarize findings from preclinical and clinical studies on this combination therapy.
- To discuss optimal scheduling and dosing strategies for improved treatment outcomes.
Main Methods:
- Review of preclinical and clinical studies on radiotherapy and angiogenesis inhibition.
- Analysis of the impact of radiotherapy dose and schedule on tumor angiogenesis.
- Evaluation of transient radiosensitizing effects of angiogenesis inhibition.
Main Results:
- Radiotherapy can modulate tumor angiogenesis.
- Angiogenesis inhibition can enhance radiotherapy's effectiveness.
- The radiosensitizing effects of angiogenesis inhibitors are temporary and schedule-dependent.
Conclusions:
- Combining radiotherapy with angiogenesis inhibitors offers a promising strategy for cancer treatment.
- Careful consideration of treatment scheduling and dosing is essential for optimizing efficacy and reducing toxicity.
- Ongoing clinical trials and further research are needed to refine this combination therapy.
Related Concept Videos
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.